LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES

The major medical problem in the treatment of skin melanoma is improvement methods of treatment, increasing their effectiveness and safety. In this study, adoptive immunotherapy, using lymphocytes activated in vitro, was performed in 15 patients with metastatic melanoma. Evaluated the phenotype of p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. V. Abakushina, Yu. V. Marizina, G. S. Neprina, D. V. Kudryavtsev, G. T. Kudryavtseva, N. V. Selivanova
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2015
Materias:	the adoptive immunotherapy the activated lymphocytes skin melanoma phenotype of peripheral blood lymphocytes Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/73c8ab97932f4959a8c0ee8ccde39551
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73c8ab97932f4959a8c0ee8ccde39551
record_format	dspace
spelling	oai:doaj.org-article:73c8ab97932f4959a8c0ee8ccde395512021-11-18T08:03:44ZLYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES1563-06252313-741X10.15789/1563-0625-2014-6-567-576https://doaj.org/article/73c8ab97932f4959a8c0ee8ccde395512015-01-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/770https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe major medical problem in the treatment of skin melanoma is improvement methods of treatment, increasing their effectiveness and safety. In this study, adoptive immunotherapy, using lymphocytes activated in vitro, was performed in 15 patients with metastatic melanoma. Evaluated the phenotype of peripheral blood lymphocytes and activation markers (HLA-DR, CD25, CD314, CD38, CD69) before and 3-4 weeks after immunotherapy. It is shown that for these patients is characterized by increasing the number of CD25+ and Treg lymphocytes in the bloodstream, which has not changed after immunotherapy. Adoptive immunotherapy in combination with chemotherapy resulted in a decrease of absolute number of lymphocyte, B- and T-lymphocytes, T helper cells, NKT-cells, CD314+ lymphocytes, CD38+ lymphocytes and immature T-lymphocytes (CD3+CD38+) (р < 0,05). However, there was a positive dynamic to increase the percentage of NK-cells to 32% and CD69+NK-cells to 21% and significant increase in expression of HLA-DR on all lymphocytes (p < 0.05). Adoptive immunotherapy characterized by the absence of side effects and can be recommended as accompanying to basic radiation and chemotherapy.E. V. AbakushinaYu. V. MarizinaG. S. NeprinaD. V. KudryavtsevG. T. KudryavtsevaN. V. SelivanovaSPb RAACIarticlethe adoptive immunotherapythe activated lymphocytesskin melanomaphenotype of peripheral blood lymphocytesImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 16, Iss 6, Pp 567-576 (2015)
institution	DOAJ
collection	DOAJ
language	RU
topic	the adoptive immunotherapy the activated lymphocytes skin melanoma phenotype of peripheral blood lymphocytes Immunologic diseases. Allergy RC581-607
spellingShingle	the adoptive immunotherapy the activated lymphocytes skin melanoma phenotype of peripheral blood lymphocytes Immunologic diseases. Allergy RC581-607 E. V. Abakushina Yu. V. Marizina G. S. Neprina D. V. Kudryavtsev G. T. Kudryavtseva N. V. Selivanova LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
description	The major medical problem in the treatment of skin melanoma is improvement methods of treatment, increasing their effectiveness and safety. In this study, adoptive immunotherapy, using lymphocytes activated in vitro, was performed in 15 patients with metastatic melanoma. Evaluated the phenotype of peripheral blood lymphocytes and activation markers (HLA-DR, CD25, CD314, CD38, CD69) before and 3-4 weeks after immunotherapy. It is shown that for these patients is characterized by increasing the number of CD25+ and Treg lymphocytes in the bloodstream, which has not changed after immunotherapy. Adoptive immunotherapy in combination with chemotherapy resulted in a decrease of absolute number of lymphocyte, B- and T-lymphocytes, T helper cells, NKT-cells, CD314+ lymphocytes, CD38+ lymphocytes and immature T-lymphocytes (CD3+CD38+) (р < 0,05). However, there was a positive dynamic to increase the percentage of NK-cells to 32% and CD69+NK-cells to 21% and significant increase in expression of HLA-DR on all lymphocytes (p < 0.05). Adoptive immunotherapy characterized by the absence of side effects and can be recommended as accompanying to basic radiation and chemotherapy.
format	article
author	E. V. Abakushina Yu. V. Marizina G. S. Neprina D. V. Kudryavtsev G. T. Kudryavtseva N. V. Selivanova
author_facet	E. V. Abakushina Yu. V. Marizina G. S. Neprina D. V. Kudryavtsev G. T. Kudryavtseva N. V. Selivanova
author_sort	E. V. Abakushina
title	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
title_short	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
title_full	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
title_fullStr	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
title_full_unstemmed	LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
title_sort	lymphocyte phenotype in patients with skin melanoma after immunotherapy of activated lymphocytes
publisher	SPb RAACI
publishDate	2015
url	https://doaj.org/article/73c8ab97932f4959a8c0ee8ccde39551
work_keys_str_mv	AT evabakushina lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes AT yuvmarizina lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes AT gsneprina lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes AT dvkudryavtsev lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes AT gtkudryavtseva lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes AT nvselivanova lymphocytephenotypeinpatientswithskinmelanomaafterimmunotherapyofactivatedlymphocytes
_version_	1718422426649362432

LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES

Ejemplares similares